Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Detrusor Hyperreflexia: later-stage trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Detrusor Hyperreflexia: 3 US clinical trials tracked, none currently recruiting.
Detrusor Hyperreflexia is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Watson Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition detrusor-hyperreflexia
OPEN 0 | RECR 0% | LATE 2 | EARLY 1 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Detrusor Hyperreflexia has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Detrusor Hyperreflexia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Detrusor Hyperreflexia is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
Watson Pharmaceuticals
NCT00224016
Botulin-A Toxin Instillations and Overactive Bladder
Mayo Clinic
NCT00583219
A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
Watson Pharmaceuticals
NCT00224029
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Detrusor Hyperreflexia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Detrusor Hyperreflexia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Detrusor Hyperreflexia page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Detrusor Hyperreflexia trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Watson Pharmaceuticals sponsors the most Detrusor Hyperreflexia trials on record, review their full trial history before evaluating a specific study. See Watson Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Detrusor Hyperreflexia condition card totals 3 registered trials; most-linked intervention Dimethyl sulfoxide (DMSO); top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.